Moderna plant in Montreal: 100 million doses of mRNA vaccine per year | Coronavirus

The new pharmaceutical facilities will include a research center and a manufacturing facility for messenger RNA (mRNA) vaccines, which will enable the production of 100 million doses annually in Quebec, announced Prime Minister Justin Trudeau.

This, in addition to creating hundreds of new jobs, will allow Canada to significantly strengthen its organic manufacturing capabilities, Mr. Trudeau pointed out.

In addition to producing vaccines against COVID-19, this state-of-the-art facility will enable the production of vaccines against a range of other diseases, including influenza.

It will also be Moderna’s first work outside of the United States. Construction is scheduled to be completed in 2024.

The exact location of the future facilities is still being negotiated. It’ll be here in the greater Montreal area, but it’s a decision Moderna will make in due course.said Justin Trudeau.

For his part, Quebec Premier François Legault welcomed the arrival of this world player in life sciences in Quebec, which includes the construction of a $180 million facility.

entreprises et plus de 36000emplois de qualité, sans compter les centres de recherche”,”text”:”L’arrivée de Moderna est hautement stratégique pour le Québec. […] Elle va sérieusement renforcer l’écosystème québécois des sciences de la vie […] On parle d’un secteur regroupant déjà plus de 700entreprises et plus de 36000emplois de qualité, sans compter les centres de recherche”}}”>The arrival of Moderna is of high strategic importance for Quebec. […] It will seriously strengthen Quebec’s life sciences ecosystem […] We are talking about a sector that already includes more than 700 companies and more than 36,000 high-quality jobs, not counting research centersadded François Legault.

Hundreds of millions in research and development

Moderna will not only make messenger RNA vaccines here. The company also counts invest heavily in R&D and conduct clinical trials here at homedeclared the Federal Minister of Innovation, Science and Industry, François-Philippe Champagne, who played a key role in the arrival of medicines in Quebec.

The entire ecosystem will benefit directly from this multi-hundred million dollar investment. We are talking about a flagship investment in research and development. »

A quote from François-Philippe Champagne, Federal Minister for Innovation, Science and Industry

Quebec will become one of the world’s few centers of excellence for messenger RNA. This is a giant leap for our life sciences industryFor his part, stressed the Minister of Economy and Innovation of Quebec, Pierre Fitzgibbon.

Pleased with the reception warm Receiving in Canada and Quebec, Moderna President Stéphane Bancel spoke of a ten-year partnership agreement with Canada and its scientists, including those at McGill University, with which Moderna has already signed a collaboration agreement.

He also recalled that Ottawa was one of the first-ever governments in the world to financially support the development and production efforts of the COVID-19 vaccine developed by his company amid a pandemic.

It’s a beautiful project in a beautiful country. »

A quote from Stephane Bancel, President of Moderna

The facility that we are announcing will allow many products to be manufactured and we believe this strategic tool will be of great interest to the Government of Canada.

A giant in the making

Founded in 2010 in the United States, Moderna rose to global prominence during the pandemic after developing Spikevax, a potent messenger RNA vaccine against COVID-19.

The company is currently the world’s second largest manufacturer of messenger RNA vaccines against COVID-19.

Using this technology, the company is also developing drugs with promising potential to combat other infectious diseases such as HIV, influenza, Zika, respiratory syncytial syndrome and Epstein-Barr virus (mononucleosis).

Rebuilding Canada’s Biomanufacturing Capabilities

Faced with significant shortfalls in domestic vaccine production, Canada had to scramble to secure urgent shipments of vaccines from Europe at the height of the pandemic, after the United States decided to dedicate all of its vaccine production solely to treating its population.

Once a world power in the field of biomanufacturing, Canada has been entirely dependent on the production of vaccines from other countries during the pandemic, as no Canadian factory has been able to produce vaccines using the technology.

Notably, the Trudeau government, which has pledged to rebuild the country’s biomanufacturing capacity, committed $2.2 billion for this purpose in April 2021, on top of deals with Axelera, BioVectra, Resilience, Novavax and Sanofi.

Yes, we are better equipped today, not only for the current situation, but for the coming decades.assured the Minister of Innovation, Science and Industry, François-Philippe Champagne.

Leave a Comment